-
1Academic Journal
Συγγραφείς: Uzunyan, Narine Adolfovna
Πηγή: Themed collection of papers from Foreign international scientific conference «Joint innovation - joint development». Part 2. by HNRI «National development» in cooperation with PS of UA. October 2023. - Harbin (China). :94-103
Θεματικοί όροι: Autotransplantation of teeth, dental surgery, treatment planning, Аутотрансплантация зубов, зубосохраняющая операция, планирование лечения
-
2Report
Θεματικοί όροι: междисциплинарный подход, ретенция, retention, дентальные имплантаты, взрослых пациентов, treatment planning, adult patients, ортодонтическое лечение, biomechanics, interdisciplinary approach, limitations of therapy, dental implants, планирование лечения, ограничения терапии, orthodontic treatment, биомеханика
-
3Academic Journal
Συγγραφείς: Uzunyan, Narine Adolfovna
Θεματικοί όροι: Autotransplantation of teeth, dental surgery, treatment planning, Аутотрансплантация зубов, зубосохраняющая операция, планирование лечения
Relation: https://zenodo.org/records/10034775; oai:zenodo.org:10034775; https://doi.org/10.5281/zenodo.10034775
-
4Report
Συγγραφείς: Кисембо, Питер
Συνεισφορές: Бразовский, Константин Станиславович
Θεματικοί όροι: оптимизация, лучевая терапия, алгоритм, программное обеспечение с открытым исходным кодом, планирование лечения, optimisation, radiotherapy, algorithm, open-source software, treatment planning, 14.04.02, 615.849:519.6
Περιγραφή αρχείου: application/pdf
Διαθεσιμότητα: http://earchive.tpu.ru/handle/11683/71753
-
5Academic Journal
Συγγραφείς: D. Pisuk
Πηγή: Эндодонтия Today, Vol 18, Iss 1, Pp 59-64 (2020)
Θεματικοί όροι: прямая реставрация, дисколорит зубов, планирование лечения, Dentistry, RK1-715
Relation: https://www.endodont.ru/jour/article/view/863; https://doaj.org/toc/1683-2981; https://doaj.org/toc/1726-7242; https://doaj.org/article/5db05640766848d993fbb187468038ac
-
6Report
Συγγραφείς: Чума, Эдмунд Джозеф
Συνεισφορές: Сухих, Евгения Сергеевна
Θεματικοί όροι: планирование лечения и обеспечение качества, параметры с несколькими листами, лучевая терапия с модулированной интенсивностью, электронные портальные устройства, воспроизводимость, treatment planning and Quality assurance, multi-Leaf Parameters, intensity Modulated Radiotherapy, electronic Portal Imaging Devices, reproducibility, 14.04.02, 615.849:681.777
Περιγραφή αρχείου: application/pdf
Διαθεσιμότητα: http://earchive.tpu.ru/handle/11683/66648
-
7Academic Journal
Συγγραφείς: Emiliano Calvo, Viktor Grϋnwald, Joaquim Bellmunt
Πηγή: Cancer Urology; Том 10, № 4 (2014); 27-36 ; Онкоурология; Том 10, № 4 (2014); 27-36 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2014-10-4
Θεματικοί όροι: планирование лечения, рак почки, терапия второй линии, выбор последовательности терапии
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/393/410; Motzer R.J., Hutson T.E., Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27: 3584–90.; Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28: 1061–8.; Rini B.I., Halabi S., Rosenberg J.E. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422–8.; Ljungberg B., Cowan N.C., Hanbury D.C. et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58: 398–406.; Escudier B., Eisen T., Porta C. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2012;23(Suppl. 7):vii 65–71.; Motzer R.J., Hutson T.E., Cella D. et al. Pazopanib versus sunitinib in metastatic renalcell carcinoma. N Engl J Med 2013;369: 722–31.; Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81.; Levy A., Menard J., Albiges L. et al. Second line treatment of metastatic renal cell carcinoma: the Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. Eur J Cancer ;49:1898–904.; Motzer R.J., Escudier B., Oudard S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116: 4256–65.; Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–56.; Rini B.I., Escudier B., Tomczak P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931–9.; Motzer R.J., Escudier B., Tomczak P. et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14:552–62.; Harrison M.R., George D.J., Walker M.S. et al. “Real world” treatment of metastatic renal cell carcinoma in a joint communityacademic cohort: progression-free survival over three lines of therapy. Clin Genitourin Cancer 2013;11:441–50.; Matrana M.R., Duran C., Shetty A. et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 2013;49:3169–75.; Rautiola J., Utriainen T., Peltola K. et al. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma. Acta Oncol 2014;53:113–8.; Hainsworth J.D., Rubin M.S., Arrowsmith E.R. et al. Pazopanib as secondline treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: A Sarah Cannon Oncology Research Consortium Phase II trial. Clin Genitourin Cancer 2013;11:270–5.; Park K., Lee J.L., Park I. et al. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. Med Oncol 2012;29:3291–7.; Calvani N., Morelli F., Leo S. et al. Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter? Med Oncol 2012;29:1908–13.; Porta C., Procopio G., Carteni G. et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int 2011;108: E250–7.; Di Lorenzo G., Carteni G., Autorino R. et al. Phase II study of sorafenib in patients with sunitinibrefractory metastatic renal cell cancer. J Clin Oncol 2009;27:4469–74.; Dudek A.Z., Zolnierek J., Dham A. et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009;115:61–7.; Busch J., Seidel C., Kempkensteffen C. et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol 2011;60:1163–70.; Garcia J.A., Hutson T.E., Elson P. et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 2010;116:5383–90.; Bergmann L., Goebell P.J., Kube U. et al. Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptortyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study. Onkologie 2013;36:95–100.; Chen C.C., Hess G.P., Liu Z. et al. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer 2012;10:256–61.; Iacovelli R., Carteni G., Sternberg C.N. et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. Eur J Cancer 2013;49:2134–42.; Hutson T., Escudier B., Esteban E. et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after suninitib in patients with metastatic renal cell carcinoma. J Clin Oncol 2013 Dec 2. [Epub before print].; Calvo E., Escudier B., Motzer R.J. et al. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 2012;48:333–9.; Cella D. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer Treat Rev 2009;35:733–7.; Gupta K., Miller J.D., Li J.Z. et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008;34:193–205.; Wagner L.I., Wenzel L., Shaw E., Cella D. Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions. J Clin Oncol 2007;25:5058–62.; Escudier B.J., Porta C., Bono P. et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): results of a randomized double-blind, placebocontrolled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310. J Clin Oncol 2012;30(June 20 Supplement):CRA4502.; Cella D., Escudier B., Rini B. et al. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer 2013;108:1571–8.; Cella D., Escudier B., Rini B. et al. Time to deterioration (TTD) in patient-reported outcomes in phase 3 AXIS trial of axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC). Eur J Cancer 2011;47(Suppl. 1). Abstr 3006.; Rini B.I., Garrett M., Poland B. et al. Axitinib in metasta tic renal cell carcinoma:results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol 2013;53:491–504.; Escudier B., Eisen T., Stadler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356: 125–34.; Al-Marrawi M.Y., Rini B.I., Harshman L.C. et al. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to secondline VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol 2013;8:203–9.; Zimmermann K., Schmittel A., Steiner U. et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009;76:350–4.; Tamaskar I., Garcia J.A., Elson P. et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179:81–6.; Azam F., Mehta S., Harris A.L. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer 2010;46:1323–32.; Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592–603.; Rini B. New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 2010;16:1348–54.; Blesius A., Beuselinck B., Chevreau C. et al. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial. Clin Genitourin Cancer 2013;11:128–33.; Di Lorenzo G., Buonerba C., Federico P. et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol 2010;58:906–11.; Grunwald V., Seidel C., Fenner M. et al.Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGFtargeted therapies. Br J Cancer 2011;105: 1635–9.; Motzer R., Szczylik C., Vogelzang N.J. et al. Phase 3 trial of dovitinib vs sorafenib in patients with metastatic renal cell carcinoma after 1 prior VEGF pathway–targeted and 1 prior mTOR inhibitor therapy. European Congress of, Cancer 2013:Abstr LBA-34.; Motzer R., Barrios C., Kim T. et al. RECORD-3: phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with; metastatic renal cell carcinoma. J Clin Oncol 2013;31. Abstr 4504.; Danesi R., Boni J.P., Ravaud A. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications. Cancer Treat Rev 2013;39; –92.; Tabernero J., Rojo F., Calvo E. et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603–10.; O’Donnell A., Faivre S., Burris 3rd H.A. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26:1588–95.; Raymond E., Alexandre J., Faivre S. et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336–47.; Hidalgo M., Buckner J.C., Erlichman C. et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006;12:5755–63.; Tanaka C., O’Reilly T., Kovarik J.M. et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008;26:1596–602.; Atkins M.B., Hidalgo M., Stadler W.M. et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909–18.; Vogelzang N.J., Bhor M., Liu Z. et al. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network. Clin Genitourin Cancer 2013;11:115–20.; Pfizer Inc., Axitinib (AG-013736) for the treatment of patients with advanced renal cell carcinoma. FDA Oncologic Drugs Advisory Committee Briefing Document (NDA 202324), 2011.; https://oncourology.abvpress.ru/oncur/article/view/393
-
8Academic Journal
Πηγή: Onkourologiâ, Vol 10, Iss 4, Pp 27-36 (2014)
Θεματικοί όροι: качество жизни, рак почки, терапия второй линии, выбор последовательности терапии, планирование лечения, Medicine
Relation: http://oncourology.abvpress.ru/index.php/oncur/article/view/393; https://doaj.org/toc/1726-9776; https://doaj.org/toc/1996-1812; https://doaj.org/article/a5841104a5a940ea992de29b1d11c9da
Διαθεσιμότητα: https://doaj.org/article/a5841104a5a940ea992de29b1d11c9da
-
9Academic Journal
Συγγραφείς: Быстрицкая, Дарья, Тихоновская, М., Мещерякова, Л., Кузнецов, В., Давыдова, И.
Θεματικοί όροι: ЗЛОКАЧЕСТВЕННАЯ ТРОФОБЛАСТИЧЕСКАЯ ОПУХОЛЬ, ХОРИОКАРЦИНОМА, СТАНДАРТНАЯ ХИМИОТЕРАПИЯ, ФАКТОРЫ ПРОГНОЗА, ПЛАНИРОВАНИЕ ЛЕЧЕНИЯ, КЛАССИФИКАЦИЯ
Περιγραφή αρχείου: text/html
-
10Academic Journal
Συγγραφείς: Быстрицкая, Дарья, Тихоновская, М., Мещерякова, Л., Кузнецов, В., Давыдова, И.
Περιγραφή αρχείου: text/html
-
11
-
12Academic Journal
Πηγή: Российский онкологический журнал.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, 3. Good health, ЗЛОКАЧЕСТВЕННАЯ ТРОФОБЛАСТИЧЕСКАЯ ОПУХОЛЬ, ХОРИОКАРЦИНОМА, СТАНДАРТНАЯ ХИМИОТЕРАПИЯ, ФАКТОРЫ ПРОГНОЗА, ПЛАНИРОВАНИЕ ЛЕЧЕНИЯ, КЛАССИФИКАЦИЯ
Περιγραφή αρχείου: text/html
-
13Academic Journal
Πηγή: Российский онкологический журнал.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, 3. Good health, ЗЛОКАЧЕСТВЕННАЯ ТРОФОБЛАСТИЧЕСКАЯ ОПУХОЛЬ, ХОРИОКАРЦИНОМА, СТАНДАРТНАЯ ХИМИОТЕРАПИЯ, ФАКТОРЫ ПРОГНОЗА, ПЛАНИРОВАНИЕ ЛЕЧЕНИЯ, КЛАССИФИКАЦИЯ
Περιγραφή αρχείου: text/html
-
14Academic Journal
Συγγραφείς: Emiliano, Calvo, Viktor, Grϋnwald, Joaquim, Bellmunt
Πηγή: Онкоурология.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, КАЧЕСТВО ЖИЗНИ,РАК ПОЧКИ,ТЕРАПИЯ ВТОРОЙ ЛИНИИ,ВЫБОР ПОСЛЕДОВАТЕЛЬНОСТИ ТЕРАПИИ,ПЛАНИРОВАНИЕ ЛЕЧЕНИЯ
Περιγραφή αρχείου: text/html
-
15Academic Journal
Συγγραφείς: Апресян С.В., Степанов А.Г., Ретинская М.В., Суонио В.К.
Πηγή: Российский стоматологический журнал
Θεματικοί όροι: цифровое планирование, стоматологическое лечение, цифровая стоматология, качество жизни, планирование лечения, Diagnocat, 3Shape, Exocad, Avantis 3D, digital planning, dental treatment, digital dentistry, quality of life, treatment planning
Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/67603/
